Fabio Ciceri

Research interests

Publications

• Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations

  Blood · 2023 · https://doi.org/10.1182/blood.2023020578

• COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

  Journal of Hematology & Oncology · 2021 · https://doi.org/10.1186/s13045-021-01177-0

• Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2021.12.003

• Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths

  Science Immunology · 2021 · https://doi.org/10.1126/sciimmunol.abl4340

• Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy

  Clinical Immunology · 2020 · https://doi.org/10.1016/j.clim.2020.108509

• Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors

  Brain Behavior and Immunity · 2020 · https://doi.org/10.1016/j.bbi.2020.07.037

• Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the acute leukemia working party of the European Society for Blood and Marrow Transplantation

  Bone Marrow Transplantation · 2020 · https://doi.org/10.1038/s41409-020-0970-x

• Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients

  Bone Marrow Transplantation · 2020 · https://doi.org/10.1038/s41409-020-0803-y

• Autoantibodies against type I IFNs in patients with life-threatening COVID-19

  Science · 2020 · https://doi.org/10.1126/science.abd4585

• Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

  Blood · 2020 · https://doi.org/10.1182/blood.2020007732

• Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation

  The Lancet Haematology · 2020 · https://doi.org/10.1016/s2352-3026(19)30256-x

• Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors

  Clinical Microbiology and Infection · 2020 · https://doi.org/10.1016/j.cmi.2020.10.021

• Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation

  Nature Medicine · 2019 · https://doi.org/10.1038/s41591-019-0400-z

• Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AML

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1902688

• Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)

  Haematologica · 2019 · https://doi.org/10.3324/haematol.2019.229781

• Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

  The Lancet · 2019 · https://doi.org/10.1016/s0140-6736(19)32556-5

• Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells

  Nature Medicine · 2018 · https://doi.org/10.1038/s41591-018-0036-4

• Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells

  Nature Medicine · 2018 · https://doi.org/10.1038/nm.4484

• Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation

  Bone Marrow Transplantation · 2016 · https://doi.org/10.1038/bmt.2016.130

• Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT

  Bone Marrow Transplantation · 2016 · https://doi.org/10.1038/bmt.2016.167

• Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome–positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

  Cancer · 2016 · https://doi.org/10.1002/cncr.30130

• Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives—a position statement from the European Society for Blood and Marrow Transplantation (EBMT)

  Bone Marrow Transplantation · 2015 · https://doi.org/10.1038/bmt.2015.52

• Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients: a nationwide retrospective survey from Italy

  Bone Marrow Transplantation · 2014 · https://doi.org/10.1038/bmt.2014.231

• Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients: a nationwide retrospective survey from Italy

  Bone Marrow Transplantation · 2014 · https://doi.org/10.1038/bmt.2014.231

• Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia

  New England Journal of Medicine · 2013 · https://doi.org/10.1056/nejmoa1300874

• Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)

  Blood · 2009 · https://doi.org/10.1182/blood-2008-11-185132

• Loss of Mismatched HLA in Leukemia after Stem-Cell Transplantation

  New England Journal of Medicine · 2009 · https://doi.org/10.1056/nejmoa0811036

Current projects

No projects listed.